Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Pharma in Focus Jobs
Brooker Consulting
Latest News
Generic price rise would show 'system is working': Ley
Reimbursement: Health Minister Sussan Ley won't confirm that a generic price rise will be announced next week but says, if so, it would show the government's commitment to access.
Minister fronts rank-and-file forum
Government Relations: Health Minister says the meeting with 53 pharma employees tackled tricky topics like medicine access and harmonising of governance and ethics in public hospital clinical trials.
Pfizer hails 60 years in Aust
Anniversary: A new innovation agreement and a $20 million boost in R&D announced at a reception attended by Health Minister Sussan Ley.
GSK outperforms Q3 expectations
Companies: GlaxoSmithKline has reported a better than expected third quarter for 2016, due in part to post-Brexit decline in the value of the British pound.
Melb Uni joins Pfizer R&D network
Industry Engagement: Melbourne Uni has become one of Pfizer's Centres for Therapeutic Innovation, which connect the company's drug development expertise with academic medical centres around the world.
Teva takes lifestyle approach for new contraceptive
Marketing: Teva, about to launch a longer-acting contraceptive, has surveyed women on their contraceptive use and found perhaps they could do with such a pill.
Most Popular
Pfizer free to block Lyrica rivals
Patent Litigation: Federal Court rejects patent invalidity claims by both Apotex and Generic Partners - though Apotex is looking at appeal options.
Gilead not alone in fast PBS growth
Reimbursement: Our analysis of the latest PBS figures shows that although Gilead is far outstripping all others in growth terms, it's not alone in growing fast.
Court disrupts patent landscape
Legal: Federal Court decision throws the right of local licensees to defend patent infringements into question.
Generics warned not to spend price increases
Reimbursement: Generic companies that benefitted from price increases recently granted by Sussan Ley have been warned not to pass the revenue on to pharmacies.
Cancer groups give pharma a tick
Patient Views: Survey finds improvements in perception of pharma's handling adverse news about products, ethical marketing practices and patient access to clinical trials.
ACCC may target 'pay for delay'
Patent Reform: A 'pay for delay' monitoring and reporting regime proposed by the Productivity Commission could create additional burdens and costs for pharma companies, says a new legal analysis.
MSD boosted by vaccine boom
Companies: MSD's Gardasil increased third quarter sales by 38 per cent but flagship drugs Keytruda and Zepatier were rated by market analysts as "weak".
Novartis volume up, value down
Companies: Novartis has reported an increase in sales volume for the third quarter of 2016 but a fall in sales value as generic competition bit.
Merged pharmacies re-brand
Retail: After a shareholder vote approving their merger, Terry White and Chemmart have moved to re-brand 500 pharmacies with a new name that won't surprise anyone.
Pipeline Monitor
Keytruda wins first-line lung cancer race
MSD's Keytruda has beaten its rivals in gaining first-line approval in lung cancer while BMS filed its immune inhibitor Opdivo in advanced bladder cancer this week.
Debating Point
Code under question
The Medicines Australia Code of Conduct imposes significant restrictions on what members of the association can do but is the compliance load it represents becoming too big a burden, sometimes for those who are not even a party to it.
Approvals Action
Generics makers add to brands
In a week when originators stayed on the sidelines generics makers added new brands to the ARTG.
Debating Point
Australia's hidden 'free' drug system
Australia's pharmaceutical industry is giving away billions of dollars worth of drugs each year and almost no-one outside industry and government knows about it.
FREE Content
Events & Conferences
Pharma in Focus Jobs
Ascott Sales
Women in Pharma Leadership